Biotech News
Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments
ir.ymabs.com2026-05-06 15:01 EST
Reported Net Product Revenues of $20.9 million for the first quarter of 2025, a year-over-year increase of approximately 8% National Comprehensive Cancer Network ® (NCCN ® ) Clinical Practice Guidelines in Oncology for Neuroblastoma updated to include naxitamab-gqgk (DANYELZA ® ) Dosed first